183 related articles for article (PubMed ID: 19441164)
1. CpG island methylation profiling in human melanoma cell lines.
Tellez CS; Shen L; Estécio MR; Jelinek J; Gershenwald JE; Issa JP
Melanoma Res; 2009 Jun; 19(3):146-55. PubMed ID: 19441164
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
6. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
7. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
9. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
[TBL] [Abstract][Full Text] [Related]
10. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
12. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer.
Topaloglu O; Hoque MO; Tokumaru Y; Lee J; Ratovitski E; Sidransky D; Moon CS
Clin Cancer Res; 2004 Apr; 10(7):2284-8. PubMed ID: 15073103
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
14. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
[TBL] [Abstract][Full Text] [Related]
15. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
16. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
17. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.
Hou P; Liu D; Dong J; Xing M
Cell Cycle; 2012 Jan; 11(2):286-95. PubMed ID: 22189819
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
19. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation.
Kaneda A; Tsukamoto T; Takamura-Enya T; Watanabe N; Kaminishi M; Sugimura T; Tatematsu M; Ushijima T
Cancer Sci; 2004 Jan; 95(1):58-64. PubMed ID: 14720328
[TBL] [Abstract][Full Text] [Related]
20. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.
Rastetter M; Schagdarsurengin U; Lahtz C; Fiedler E; Marsch WCh; Dammann R; Helmbold P
Histol Histopathol; 2007 Sep; 22(9):1005-15. PubMed ID: 17523078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
